Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Hello and welcome to BICO AB Group's quarter three 2025 Earnings Call. I'm Maria Forss, President and CEO, and I will, together with BICO AB CFO Jacob Thordenberg, present this interim report. Here's today's agenda. I will open today's session by presenting how BICO AB serves the world's leading pharma and biotech companies with solutions that transform how labs operate and innovate. Following that, Jacob will provide a summary of the quarter's key developments and present the group's financial performance. We will proceed and comment on our two business areas: Life Science Solutions and Lab Automation. Additionally, we will highlight our R&D pipeline with ongoing product development efforts, and this session will conclude with final remarks before opening up for Q&A. At BICO AB, we serve the world's leading pharma and biotech companies. Our portfolio ranges from Biosero. Our market-leading Green Button Go software enables full lab orchestration, from off-the-shelf automation products to bioprinting from our life science solutions business. Our solutions enable smarter, faster and more efficient labs, and therein lies a strong underlying demand. Pharma and biotech companies face the same fundamental challenge: long and costly development cycles for new therapies. The development of a new therapy often takes more than ten years and costs between 2 and 4 billion USD, where 90% of the pipeline ultimately fails. To overcome this, these companies are investing heavily in automation to increase efficiency, speed, and quality, bringing innovations to the market faster and at a lower cost. The next wave of automation goes beyond instrument orchestration to connect entire workflows and data streams, where AI and machine learning continuously optimize experimentation and decision-making. And BICO AB is at the core of this development, providing the data backbone that unifies AI-powered services with lab automation. Our products and services enable our customers to connect data across diverse informatics systems and apply AI tools to plan, run, and optimize experiments in real-time. And already today, we are powering AI drug discovery workflows that follow the design, make, test, analyze paradigm using our Green Button Go platform. Further, we integrate AI-driven image analysis as high-throughput analytical tools into cell line development workflows, enhancing speed and precision in bioprocess optimization. Today, researchers spend too much time on manual tasks and fragmented data, resulting in wasted samples and stalled projects. Combined with macroeconomic pressures, talent shortages, and tighter budgets, automation has become not just a competitive advantage, but a necessity for the future of discovery. BICO AB is at the core of this transformation, connecting workflows and data streams and enabling AI-powered experimentation. And this is what our mission and vision are all about. Our vision is to enable and automate the life science lab of the future, and our mission is to be the first choice lab automation partner and provider of selected workflows to pharma companies like MatTek. And this brings us to a video I'm about to share, which shows an example of an integrated lab automation solution we have designed and delivered to one of our customers. And in my view, this truly reflects our mission. With this introduction, my aim has been to emphasize BICO's mission, our strategic direction, and the value we deliver to our customers. We lead the way in solving the challenges in life sciences with speed, accuracy, and efficiency. Speed by reducing the time to find optimal candidates for treatment therapies and supporting our customers in driving forward a personalized approach to treatment accuracy. By enabling the development of physiologically relevant models and enhancing reproducibility through automated processes that reduce variability in experimental outcomes, we develop solutions to maximize the productivity of automated lab equipment and scientists. All in all, our customers can run their processes faster, improve the quality of their data, and ultimately make better decisions. I will now hand over to Jacob to present the results for the third quarter.
Thank you, Maria. I will summarize the third quarter of 2025 for the group and then provide more financial details for the quarter, focusing on the performance of the third quarter. Life Science Solutions delivered 4% organic sales growth, in line with market performance. The growth was mainly driven by a positive uptick in diagnostics as well as increased demand for lab automation components. Science continued to perform well, delivering double-digit growth after major commercial and operational improvements in our diagnostic market, which is returning to more normal investment levels. Lab automation delivered 35% organic sales growth, rebounding after an abnormal Q2. Good progress has been made in the execution of the action plan, significantly enhancing processes, leadership, and operational capabilities. In addition, Biosero received orders from a global pharma company worth 15.2 million USD as part of a Global Master Framework agreement. This showcases the strong underlying demand for lab automation and Biosero's market-leading software suite, Green Button Go. We have also resolved impairments in Discover ECHO and Biosero totaling 1,036,000,000. These impairments will not affect cash flow but have impacted EBITDA for the quarter. With that said, I would like to highlight that we anticipate long-term growth of around 10% CAGR, which is in line with our financial targets for both Discover ECHO and Biosero. I will elaborate more about this shortly. The closing of the transaction for the divestments of MatTek and Visikol was finalized in early July. These divestments generated 740 million, which significantly strengthened our cash position. Next slide please. Q3 was a quarter of solid progress. Net sales reached 387 million, despite ongoing macroeconomic challenges and funding headwinds in key markets, with organic sales growth of 12%. We also experienced that academic and biotech funding remains constrained, especially in North America, which has led to cautious customer spending and extended sales cycles. Adjusted EBITDA amounted to 17 million, corresponding to an adjusted EBITDA margin of 5%, which is an improvement in the adjusted EBITDA margin of three percentage points year over year. The improved margin is a result of continued cost control activities, mainly due to synergies derived from the centralization of functions, as well as initiatives for operational efficiencies. Maria will now comment on the progress of the execution of the Comprehensive Action Plan to scale up Biosero.
Since September, we have a new Managing Director in Biosero with long and extensive experience in the global life science industry, and he has the right toolbox to drive sustainable growth and create long-term value for customers and shareholders. And we have made solid progress in executing the action plan, significantly strengthening not only leadership but also processes and operational capabilities. We have also continued making substantial investments in operational resources to better serve our customers and accelerate the closing of delayed projects. Furthermore, we are implementing more standardization to scale the business and introducing new commercial concepts with shorter lead times to balance the project portfolio. Also worth mentioning again, is that Biosero secured several orders from a global pharma company valued at 15.2 million USD in the quarter, and this project will develop integrated lab automation solutions which will support this Big Pharma customer's drug development process. I will now hand over to Jacob again for comments on the divestments and impairments.
Thank you. Well, in Q3, we completed the divestments of MatTek and Visikol, generating 740 million. As previously mentioned. And this significantly strengthens our cash position. And these divestments follow our updated strategy with a focus on lab automation and selected workflows. Sartorius acquired both companies at the 2024 sales multiple of 3.7 and an adjusted EBITDA multiple of 15.3x. The companies have been treated as discontinued operations from Q2 2025. And if we move on to the next slide in the quarter, we also resolved 1,036 million in impairments for Discover ECHO and Biosero, which are non-cash flow affecting one-off items but still impacting EBIT in Q3. In May 2024, we implemented an updated model for impairment with a shortened forecast period before terminal calculations, reducing it from 10 to 5 years, following the recommendation from the Swedish Financial Reporting Supervision. The impairments stemmed from a shortened forecast period and lower year-to-date trading in 2025, leading to changed forecast assumptions compared to previous periods. With that said, we see a strong underlying demand for Biosero's integrated lab automation solutions centered around the company's market-leading software suite, Green Button Go and Echo. We see a market recovery in the US academic segment. Over time, we anticipate long-term growth of around 10% CAGR in both companies, which is also in line with our financial targets. I will now move on to the next section. Group financial performance. In Q3, sales amounted to 387 million and grew 5% in total and 12% in organic sales growth. The difference of seven percentage points is mainly explained by a weaker US dollar against the Swedish krona. Adjusted EBITDA amounted to 17 million, corresponding to a margin of 5%. The improved margin is a result of continued cost control activities, mainly from the centralization of functions, as well as initiatives for operational efficiencies. And if we move on to Q3 cash flow. Cash flow from operating activities amounted to -32 million, impacted by working capital changes of -30 million. Total cash flow during the quarter amounted to 570 million. As mentioned before, MatTek and Visikol were divested as of July 1st, 2025, generating net proceeds of 740 million. We also made a third bond buyback in our convertible debt in August 2025, which amounted to 98 million. So in connection to this, I will also comment on BICO's outstanding convertible debt and our cash position. In total, we have made three buybacks in our convertible bond between November 2024 and August 2025, totaling a nominal amount of 492 million. The rationale for the bond buybacks has been to optimize BICO's capital structure and further reduce long-term debt, post buybacks. The convertible debt now amounts to a nominal 1,008,000,000 as per Q3. As mentioned on the previous slides, the effects of changes in working capital amounted to -30 million for the quarter, and out of this, operating receivables increased by 96 million. Inventories increased by 1 million, and operating liabilities increased by 65 million. In percentage of last 12-month sales, net working capital in the quarter corresponded to 13%, confirming that the operational excellence actions implemented in 2023 and onwards have been successful for Q1 up until Q3 in 2025. The further decrease in net working capital to low double digits is primarily an effect of less net working capital in Biosero, due to decreases in receivables. I will now hand over to Maria to present the results in our two business areas.
Thank you, Jacob Thordenberg. Let's now turn to our largest business area, Life Science Solutions, which accounted for two-thirds of our revenue. This quarter, Life Science Solutions delivered 263 million in sales, with 4% organic sales growth and an adjusted EBITDA of 19 million, corresponding to a 7% adjusted EBITDA margin. The growth was mainly driven by a positive uptake in diagnostics, as well as increased demand for lab automation. Components continued to perform well, delivering double-digit growth after major commercial and operational improvements in the diagnostic market, which is returning to more normal investment levels. And if we move on to our business area, Lab Automation, in quarter three, Lab Automation delivered 35% organic sales growth year over year, rebounding after the abnormal quarter two. The business area sales for the quarter amounted to 124 million. The adjusted EBITDA was 10 million, corresponding to an adjusted EBITDA margin of 8%. Reversing the negative trend from the recent quarters. Profitability is still impacted, though, by continued substantial investments in operational resources for the benefit of our customers to accelerate the closing of projects. As mentioned earlier in this presentation, good progress has been made during the quarter in executing the Comprehensive Action Plan to scale Biosero. I will now introduce a new section where I will share our data on our ongoing product innovation efforts. One focus area for growth is continuous product innovation. BICO AB has a solid R&D pipeline and roadmap in place, and this is based on the portfolio strategy, which is part of BICO AB 2.0. Our current product portfolio covers the full spectrum of lab automation solutions and selected workflows. And it's important to emphasize that we have lab automation products and solutions in both of our business areas. And this is illustrated on this slide where you can see instruments from various BICO AB business units positioned along different stages of the lab automation continuum. Products in the business area, Life Science Solutions, are also Green Button Go ready. In BICO AB, we invest substantially in product development. We're continuing to bring new products and innovations to the market, and recent product launches include Highlight and Turn Station. The highlight is a new addition to the series and offers a compact solution optimized for automated, low-volume liquid dispensing. This product, Green Button Go ready Turn Station by Q Instruments, is a lab automation device for liquid handlers. It optimizes workflows for microplate handling and is purpose-built for seamless lab automation. This is an example of how we are driving growth through synergies in the BICO AB group. Let's now move on to an example of a successful product launch from an ongoing external collaboration. This is a result of the scientific collaboration between Sartorius and BICO AB, specifically focusing on the Sartorius Octet and Biosero. Green Button Go is an integrated solution delivering faster results to the market, enabling labs to operate more efficiently and effectively. And these were just a few examples of recent launches and collaborations. Let's now move on to look at the R&D pipeline and roadmap. We have a comprehensive product development pipeline within our prioritized focus areas, as you can see on this slide. The majority of the R&D investments are made in software development. While there are several upgrades to the instrument portfolio meeting customer needs, multiple product launches are planned for 2026, including both software instruments and consumable products. As mentioned before, we are also introducing new commercial concepts in lab automation with shorter lead times to balance the product portfolio. And these concepts are developed both through internal collaboration between the two business areas, as well as with external collaborators. Before the Q&A, I will give some concluding remarks. One year ago, we launched BICO AB 2.0, which is our updated strategy to enable and automate the life science lab of the future. Since then, we have streamlined our portfolio. We have strengthened our commercial engine, invested in our people and culture, and delivered operational excellence. It's been a year of change, and we have worked hard. The impact that we together have achieved is clear: significantly strengthened cash position, leaner operations, and more customer-centric solutions. And this is just the beginning. We're excited to drive lab automation forward and equip pharma companies with tools to shorten drug development timelines. I would also like to take the opportunity to thank our customers for your continued trust in BICO AB, as well as our employees around the world for your work and dedication, which enable our customers to deliver what matters the most: the discoveries that advance human health. This was our final slide before the Q&A. I will hand over to the earnings call host for further instructions.
If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.
Thank you very much and good morning. A few questions on my end. And if we can start off with lab automation and you talk about healthy demand in lab automation, could you clarify what that entails? Okay.
Well, as we can see in the quarter, we are landing substantial orders of more than 15.2 million USD. And we continue to see demand also from other big pharma customers. And that's the basis for our claim of healthy demand.
And just to sort of clarify. Are you seeing increased tender activity? Are you seeing a growing order intake, or is there a customer assessment of your software to get some sense of how this could be quantified?
As you know, we do not provide guidance or discuss our order stock or order intake due to competitive reasons. We have several ongoing discussions with customers and a healthy business.
And I know that you don't quantify order intake, but in terms of any granularity, has this improved over the last six months regarding customer interest, or how should we view this?
I think that the customer interest has been retained. As we have talked about in previous calls and will discuss today as well, the first half of 2025 has been challenging for us and many of our peers. And that has also been reflected in not the demand, but the time it takes to close orders, and some of those orders are now being executed.
Do you expect the timeline from initial interest to closing the deal to have shortened, or is it still the same?
When you have master service agreements with large pharma customers or customers overall? Of course, those will facilitate the time it takes to get orders in place.
Are you seeing a growing order intake or is there customer assessment of your software to get some sense of how this could be quantified? And again on lab automation, you've made some structural changes in the management of these contracts. Does this apply to the newly assigned contract, the one you signed in September, or is this under the same type of agreement that you had prior to the restructuring?
We have changed the way we are operating overall, both in terms of how we run projects, how we are scoping the projects, and the way we are structuring the contracts to ensure clarity moving forward. So I would say it's a new way of working that has been implemented since earlier this year, which is now starting to show effect.
Are you seeing a growing order intake or is there customer assessment of your software just to get some sense on how this could be quantified? And on the phasing of this 50 million US contract, should we sort of assume and apply the same type of phasing that we have seen historically, which has been a lot of revenue and profit being frontloaded, and then that being tapered off gradually throughout '26, when it's set to be delivered throughout '26 as well?
Yeah, maybe I can answer that question. And the short answer is yes. And that is due to the revenue recognition profile that we have in Biosero, which is based on the percentage of completion. And our percentage of completion model is based on anticipated costs. And in these projects, a large chunk of the anticipated costs is indeed related to hardware. And roughly speaking, the other part of the anticipated cost is labor hours. Given that we typically buy a lot of instruments when we start a project, you usually see a spike in revenues due to the purchase of hardware, which is quite a significant share of the anticipated costs. Then you have less acceleration in revenue recognition related to the labor hours. So yes, it has a similar profile as you have seen from previous large orders.
And I guess you assume, given your outlook, that you will be signing new orders to bridge that gap into 26.
Not sure I follow that question, Eric.
Given the tapering off of revenues into 2026, in order for you to grow from that level in absolute terms, you would need to add additional contracts.
Yes. Correct? Yes.
Great. And just on the discontinuation effects, both in the quarter as well as for Q4, is it possible to quantify what sort of actual numbers we should be modeling for?
We don't have any effect from MatTek and Visikol in the quarter, given that they were completely out of our books as of July 1st.
Yes, but if it's possible to quantify, I know that you've restated it for general modeling purposes.
Or, but there's, there's.
There is nothing in our books in Q3, so there's nothing to quantify because the assets are not in our economic ownership anymore during the quarter.
Sure. But from a comparable perspective, in Q3 last year, they were in your books and in reported numbers.
And yes, but that has been a deviation.
In the report. So there's no effect in the report. It has been excluded in the comparison.
Yeah, sure. Yeah, yeah.
But okay. But if we were to quantify it for Q4, then I guess you reported some sales in Q4 for some of the subsidiaries.
Yeah. Correct? Correct?
So you want the comparison figure for Q4 last year. I can perhaps provide you with that separately. I don't have those numbers in my head right now.
Okay, great.
And just two last questions on my end. I note that sales expenses are down sequentially while your topline is up. Is there something to read into that, or are you doing something different in terms of your selling expenses? And secondly, where is the steady state working capital level relative to the top line in percentage terms?
Yeah.
Do you want to answer the first question in terms of?
I think overall we have, as we have talked about earlier, ensured that we can achieve both commercial and operational synergies within the group, as well as with our sales skills group and other commercial skills groups. We are then reaping those synergies. Part of the cost management that Jacob Thordenberg talked about earlier in the call is about those synergies, but also centralizing some functions as well as improving operational efficiency. So that's where the improvement in the margin comes from. And secondly, where is kind of sort of a steady state, like working capital level to top line in percentage terms? And then,
I can ask the second question regarding working capital in relation to sales. As we mentioned in the call, we're very happy to see that we have made great progress in our working capital, and it is now down to 13% in relation to LTM sales. We do believe that a stable level should be between 15% and 20% of sales.
And secondly, where is kind of sort of a steady state, like working capital level to top line in percentage terms?
That's a fine level. That was all the questions on my end, and I'll get back into the queue. Thank you.
And secondly, where is a kind of steady state like working capital level to top line in percentage terms?
Julie.
The next question comes from Ludvig Lundgren from Nordea. Please go ahead.
Yes. Hi and thank you for taking my questions. So continuing, lab automation sales were positively affected by the order you received in September. So I just wonder if you could elaborate a bit more on the effect we saw here in Q3 and whether the positive contribution will increase sequentially as we move into Q4.
That's a good question, Ludvig. And I expect to see a similar type of impact in Q4. I won't disclose how much the impact will be, but we saw a positive impact from the purchase of hardware in Q3, and we will see a similar impact also in Q4.
Perfect. And then, yeah, great. And then also on lab automation. So I think the median reported EBITDA margin in the last three years is close to the current level, actually at 8%. present. So I just wonder if you can provide some insight into the current margin levels and whether it's reasonable to expect a significant increase in margins for lab automation as we move into 2026, considering you've highlighted some elevated costs here in Q3 as well.
Yeah, I won't go into specifically commenting on what kind of margin we can expect. But we do have higher ambitions for the cost base in Biosero, and we expect to be able to scale that cost base in a more efficient way going into 2026. And by that, of course, we also aim to expand our EBITDA margins, which we believe could be higher than the margins we see today.
present. And so, it's largely a consulting business. Is it possible to quantify the utilization that you currently have and how many more projects you could add on this current cost base?
Yeah.
We won't go into the utilization rate, because that would be quite commercially sensitive. But we do believe that we can gain more efficiencies on the cost that we have in Biosero, and by that, also be able to take on more projects. But we won't comment specifically on what kind of utilization rate we have as of today. But we do believe that we can scale the cost base in a more efficient way in Biosero.
Perfect. present. And then finally on the framework agreement, I just wonder if you can share a bit more on the potential for further similar orders from this customer. Does this relate to only one location? And then they could possibly expand it to other locations as well. Or how should we view this in, you know, the longer term.
The framework agreement signed earlier in the quarter is a global framework agreement. And the orders that we won now in quarter three are for one project in one site, but the framework agreement applies to all the different sites for this big Pharma customer.
Okay, so is it fair to assume then if this is a successful project, they could expand this to other sites as well. Yes, that's correct.
Yes, that's correct.
Perfect.
Such a framework agreement in place facilitates the entire procurement process, which is usually quite long and tedious in large companies. So it's a very good thing to have that in place.
present. Yeah. Just a follow-up on that then. So, what would you say is the visibility for an order from this customer? Will you have some? How much visibility will you have into an order coming in, so to say?
Well, with these types of large customers. It's really a strategic collaboration. And some of these strategic collaborations usually have plans for a couple of years ahead. And then it's a dialogue between us and the customer so we can ensure that we have the capacity and resources to meet their demands when the different orders come in. So it's a good collaboration.
So, what would you say is the visibility for an order from this customer? So what would you say is the visibility for an order from this customer? That was all for me. So I'll jump back into the queue. So, what would you say is the visibility for an order from this customer?
Thank you. Ludwig.
The next question comes from Susanna Quickborn from SFB. Please go ahead.
Hello, Susanna Werner, Handelsbanken. Just to follow up on the Biosero. Regarding the write-down, perhaps you could give us a more detailed explanation of how you're thinking about this, given that you see continued high demand. But you have now reduced the forecast for 2025 and, to some extent, beyond. So maybe explain what the thinking is here and how we should think about it.
Yes.
Thank you, Susanna. Well, I think the way you should see it is that when we started 2025, we had much higher ambitions for Biosero and expected more from Biosero. And now, as we are about to conclude the year, we can see that we will not meet the expectations that we set for Biosero at the start of 2025. And by that, we also see that the implicit growth between what we expected in 2025 and what we now expect for 2026 was too ambitious, given the current trading at Biosero. But with that said, we still have high ambitions. But given the outcome in 2025 and the year-to-date trading in 2025, we realized that we had to revisit 2026. And by that, we also experienced knock-on effects for the years following 2026.
Right. And then also a question on consumables and services. You've seen an increase. Should I see this as a one-off, or are you actually making some kind of transition to selling more consumables, for example? What's happening here?
There are several initiatives to increase recurring revenue. That's one of our five focus areas commercially. And as you can also see from other peers in the industry. Consumables are going very well. We have also focused on increasing our service sales. And as you noted, Susannah, there has been an increase in this particular quarter. I think we should examine that trend over several quarters. And because there can also be an effect of the product mix, there is much focus on consumables and service overall.
Good. Right. I'll get back to you.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Philip Einerson from Redeye. Please go ahead.
Okay. Hello, everybody. I'd be curious to understand a little bit more about the operational efficiency and margin improvements we observed in Q3. Could you help us with some reasonable expectations on the opex base for the coming quarters? That's the first.
Okay. Well, in terms of the opex base, I would say that it's quite stable at the moment. We do talk in the report about having elevated costs at Biosero as we're investing in our customers. And if anything, we want to continue to scale on the current OpEx base rather than increasing costs in the coming quarters. And as we have also been quite clear, we maintain strict cost control, and we want to continue that to gain operational leverage on our current cost base.
Okay. So a short follow-up on that would be to ask about what sort of line item in the income statement you would see? You can achieve significant savings with the current outlook.
No, I don't believe we see any primary savings; quite the opposite. I do believe that we should be able to grow while keeping all lines in opex flat.
Okay. Okay. I've got one more, which is a broader type of question, but we saw that Sartorius lowered BICO AB equity exposure in the second half of 2025, and I thought maybe you could provide some additional color on this. It might be hard for you, but anyway, maybe you could also provide some commentary on the current status of the collaboration with Sartorius after the divestments. Thank you.
Yeah, I can answer the first question, and then Maria can answer the second question. And the first question is quite simple. We cannot comment on the activities of Sartorius. That's not our job to do that. It's the job of Sartorius.
And when it comes to our collaborations, we have a handful of different scientific collaborations ongoing that will eventually reach the market. And these are all going great and are evaluated on a continuous basis to make sure that assumptions and business cases are holding. And everything is fine when it comes to collaborations. And you saw an example of a result of a collaboration with Sartorius in our presentation with the Octet, powered by Green Button Go, which was launched earlier this year and has been a good commercial success so far.
Right, right. So that output was more like, you know, has there been any sort of changes in the collaboration dynamics following the recent half year of happenings? I would interpret that as a no then.
No, no.
Okay, good.
Things are going according to plan.
Okay, good. That's all for me.
The next question comes from Ludvig Lundgren from Nordea. Please go ahead.
Yes. Hi again. So just a follow-up on the cost base that you mentioned there. So R&D on a gross level has significantly decreased in the last 12 months. I think it's around 50 million now in Q3. Like, is it fair to extrapolate this level of R&D ahead, or will this increase in Q4, as you typically have somewhat of a sales increase there as well? Or for us to model this, how would you approach it?
I think it's important to understand here that we do substantial investments in R&D, and what you find in the report is capitalized. R&D is what is put on the balance sheet. And we have adopted a much more conservative approach to capitalizing R&D. So then, it's the different projects that will have to pass toll gate three in our gate stage project model before we capitalize any R&D to ensure that we have more security and success for the project. So the capitalized R&D and the level of that is not an indication of the amount of R&D that we're doing, but rather what we put on the balance sheet or not.
Hi again. I was actually referring to the gross total level, including both the amount in the P&L and in the balance sheet or in the cash flow. And that one has also decreased significantly. So just this 50 million, is that a sustainable level in the PNL then?
Yes, it is a sustainable level, and I don't foresee any changes to this. However, as Maria mentioned, we have a much more stringent model now in terms of capitalizing R&D. And that is contingent upon the different R&D projects within the group passing certain toll gates. But the level of R&D, in terms of both personnel and what's capitalized, I don't expect that to change dramatically in the coming quarters now.
Hi again. Very clear.
Okay, good.
There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Thank you for all the questions received, and thank you for your continued interest in supporting BICO AB Group together with Jacob. I wish you all a great Tuesday. Thank you and goodbye.



















